Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T63934
|
||||
| Former ID |
TTDI01921
|
||||
| Target Name |
Interferon alpha 2 ligand
|
||||
| Gene Name |
IFNA2
|
||||
| Synonyms |
IFNalpha2; Interferon alpha2; Interferon alphaA; LeIF A; IFNA2
|
||||
| Target Type |
Successful
|
||||
| Disease | Bladder cancer [ICD9: 188; ICD10: C67] | ||||
| Basal cell cancer [ICD9: 140-229, 173; ICD10: C44] | |||||
| Colorectal cancer [ICD9: 153, 154; ICD10: C18-C21] | |||||
| Hairy cell leukemia [ICD9: 202.4; ICD10: C91.4] | |||||
| HCV infection [ICD9: 070.4, 070.5, 070.70; ICD10: B17.1, B18.2] | |||||
| HBV infection [ICD9: 070.2-070.3; ICD10: B16, B18.0, B18.1] | |||||
| Mesothelioma [ICD9: 163; ICD10: C45] | |||||
| Melanoma [ICD9: 172; ICD10: C43] | |||||
| Viral infections [ICD9: 054.0, 054.1, 054.2, 054.3, 075, 771.2, 052, 053; ICD10: B01, B02, A60, B00, B27, G05.1, P35.2] | |||||
| Unspecified [ICD code not available] | |||||
| Function |
Produced by macrophages, IFN-alpha have antiviral activities.
|
||||
| BioChemical Class |
Cytokine: interferon
|
||||
| UniProt ID | |||||
| Sequence |
MALTFALLVALLVLSCKSSCSVGCDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFG
FPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEA CVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNL QESLRSKE |
||||
| Drugs and Mode of Action | |||||
| Drug(s) | Interferon Alfa-2b | Drug Info | Approved | Melanoma | [551871] |
| Peginterferon alfa-2a | Drug Info | Approved | Hairy cell leukemia | [536361] | |
| Peginterferon alfa-2b | Drug Info | Approved | HCV infection | [536361], [542487] | |
| Albinterferon alfa-2b | Drug Info | Phase 3 | HCV infection | [530007] | |
| Hebergel | Drug Info | Phase 3 | Viral infections | [529448] | |
| Interferon alpha 2a | Drug Info | Phase 3 | HCV infection | [525849] | |
| P-1101 | Drug Info | Phase 3 | HBV infection | [524444] | |
| Instiladrin | Drug Info | Phase 2 | Bladder cancer | [524056] | |
| Interferon alpha-2b | Drug Info | Phase 2 | HCV infection | [550975] | |
| Novaferon | Drug Info | Phase 2 | Colorectal cancer | [525215] | |
| CIGB-128 | Drug Info | Phase 1 | Basal cell cancer | [549462] | |
| SCH-721015 | Drug Info | Phase 1 | Mesothelioma | [523112] | |
| Modulator | Albinterferon alfa-2b | Drug Info | [530007] | ||
| CIGB-128 | Drug Info | ||||
| HAp-IFN | Drug Info | [550872] | |||
| Hebergel | Drug Info | [527899] | |||
| Instiladrin | Drug Info | [524056] | |||
| Interferon Alfa-2b | Drug Info | [556264] | |||
| Interferon alpha 2a | Drug Info | [533362] | |||
| Interferon alpha-2b | Drug Info | [550320] | |||
| Novaferon | Drug Info | [544388] | |||
| P-1101 | Drug Info | [530931] | |||
| Peginterferon alfa-2a | Drug Info | [556264] | |||
| Peginterferon alfa-2b | Drug Info | [556264] | |||
| SCH-721015 | Drug Info | [531615] | |||
| subalin | Drug Info | ||||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| Pathways | |||||
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| Regulation of autophagy | |||||
| PI3K-Akt signaling pathway | |||||
| Toll-like receptor signaling pathway | |||||
| RIG-I-like receptor signaling pathway | |||||
| Cytosolic DNA-sensing pathway | |||||
| Jak-STAT signaling pathway | |||||
| Natural killer cell mediated cytotoxicity | |||||
| Tuberculosis | |||||
| Hepatitis C | |||||
| Hepatitis B | |||||
| Measles | |||||
| Influenza A | |||||
| Herpes simplex infection | |||||
| Autoimmune thyroid disease | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| Pathway Interaction Database | Downstream signaling in na& | ||||
| #xef | |||||
| ve CD8+ T cells | |||||
| Reactome | Interferon alpha/beta signaling | ||||
| Regulation of IFNA signaling | |||||
| TRAF6 mediated IRF7 activation | |||||
| Factors involved in megakaryocyte development and platelet production | |||||
| WikiPathways | Toll-like receptor signaling pathway | ||||
| Type II interferon signaling (IFNG) | |||||
| Interferon alpha/beta signaling | |||||
| Regulation of toll-like receptor signaling pathway | |||||
| References | |||||
| Ref 523112 | ClinicalTrials.gov (NCT01162785) Phase IB Intravesical Administration of SCH 721015. U.S. National Institutes of Health. | ||||
| Ref 524056 | ClinicalTrials.gov (NCT01687244) Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer. U.S. National Institutes of Health. | ||||
| Ref 524444 | ClinicalTrials.gov (NCT01949805) Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera. U.S. National Institutes of Health. | ||||
| Ref 525215 | ClinicalTrials.gov (NCT02455596) Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors. | ||||
| Ref 525849 | Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol. 2000 Aug;18(16):2972-80. | ||||
| Ref 529448 | Detection of PEGylated proteins in polyacrylamide gels by reverse staining with zinc and imidazole salts. Electrophoresis. 2008 Jun;29(11):2363-71. | ||||
| Ref 530007 | Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin. 2009 Apr;25(4):991-1002. | ||||
| Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
| Ref 542487 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7462). | ||||
| Ref 524056 | ClinicalTrials.gov (NCT01687244) Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer. U.S. National Institutes of Health. | ||||
| Ref 527899 | Evaluation of recombinant human interferon alpha-2b structure and stability by in-gel tryptic digestion, H/D exchange and mass spectrometry. J Pharm Biomed Anal. 2006 Feb 24;40(3):781-7. Epub 2005 Nov 28. | ||||
| Ref 530007 | Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin. 2009 Apr;25(4):991-1002. | ||||
| Ref 530931 | Effects of PEG-interferon-alpha-2A on Schistosoma mansoni infection in mice. J Parasitol. 2010 Aug;96(4):703-8. | ||||
| Ref 531615 | Toxicity and exposure of an adenovirus containing human interferon alpha-2b following intracystic administration in cynomolgus monkeys. Gene Ther. 2012 Jul;19(7):742-51. | ||||
| Ref 533362 | Hairy cell leukemia associated with large granular lymphocyte leukemia: immunologic and genomic study, effect of interferon treatment. Blood. 1988 Aug;72(2):655-60. | ||||
| Ref 544388 | Novaferon, a novel recombinant protein produced by DNA-shuffling of IFN-alpha, shows antitumor effect in vitro and in vivo. Cancer Cell Int. 2014; 14: 8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.